Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...
Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia ...
In response, Dave presents a study to be discussed at the 2024 American Society of Hematology (ASH) Annual Meeting and ...
Nobel Prize in Chemistry highlights AI-driven breakthroughs in computational protein design and structure prediction. Tools ...
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection ...
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA ...
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach.
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
Patients with multiple myeloma face a complex, decades-long treatment journey involving care coordination, insurance ...
Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.
Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed ...